Taken together, these results suggest that CXCR1 and its ligands GROα and IL-8 were aberrantly expressed in brain cancer cells and that CXCR1 mediated proliferative signaling that was triggered by its ligands via the ERK1/2 pathway. This evidence concerns the gene CXCL1 and brain cancer.